{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:10:54Z","timestamp":1792714254245,"version":"4.5.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,2,27]],"date-time":"2015-02-27T00:00:00Z","timestamp":1424995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006438","name":"Office of the Assistant Secretary for Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006438","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005255","name":"Office of the Secretary","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005255","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.antiviral.2015.02.007","type":"journal-article","created":{"date-parts":[[2015,3,4]],"date-time":"2015-03-04T02:16:00Z","timestamp":1425435360000},"page":"115-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["The efficacy and pharmacokinetics of brincidofovir for the treatment of lethal rabbitpox virus infection: A model of smallpox disease"],"prefix":"10.1016","volume":"117","author":[{"given":"Lawrence C.","family":"Trost","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jody","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Keilholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Godin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.antiviral.2015.02.007_b0005","doi-asserted-by":"crossref","first-page":"11084","DOI":"10.1128\/JVI.00423-07","article-title":"Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox","volume":"81","author":"Adams","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.02.007_b0010","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.virol.2003.11.015","article-title":"Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model","volume":"318","author":"Buller","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2015.02.007_b0015","series-title":"Smallpox and Its Eradication","first-page":"121","article-title":"The pathogenesis, pathology and immunology of smallpox and vaccinia","author":"Fenner","year":"1988"},{"issue":"2","key":"10.1016\/j.antiviral.2015.02.007_b0020","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1128\/JCM.42.2.601-609.2004","article-title":"Smallpox and pan-orthopox virus detection by real-time 3\u2032-minor groove binder TaqMan assays on the roche LightCycler and the cepheid smart cycler platforms","volume":"42","author":"Kulesh","year":"2004","journal-title":"J. Clin. Microbiol."},{"issue":"12","key":"10.1016\/j.antiviral.2015.02.007_b0025","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.3390\/v2122740","article-title":"Development of CMX001 for the treatment of poxvirus infections","volume":"2","author":"Lanier","year":"2010","journal-title":"Viruses"},{"issue":"5","key":"10.1016\/j.antiviral.2015.02.007_b9000","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/AAC.05983-11","article-title":"First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses","volume":"56","author":"Painter","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.02.007_b0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.antiviral.2007.08.003","article-title":"Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model","volume":"77","author":"Parker","year":"2008","journal-title":"Antiviral Res."},{"issue":"1","key":"10.1016\/j.antiviral.2015.02.007_b0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.virol.2008.11.015","article-title":"Mousepox in the C57BL\/6 strain provides an improved model for evaluating anti-poxvirus therapies","volume":"385","author":"Parker","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2015.02.007_b0045","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.3390\/v2091918","article-title":"Ectromelia virus infections of mice as a model to support the licensure of anti-orthopoxvirus therapeutics","volume":"2","author":"Parker","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2015.02.007_b0050","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.antiviral.2012.02.005","article-title":"Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox \u2013 an animal model of smallpox","volume":"94","author":"Parker","year":"2012","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.02.007_b0055","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.antiviral.2014.08.003","article-title":"Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus","volume":"111C","author":"Parker","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.02.007_b0030","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1128\/AAC.48.2.404-412.2004","article-title":"Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir","volume":"48","author":"Quenelle","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.antiviral.2015.02.007_b0060","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/v3010047","article-title":"Efficacy of CMX001 as a post exposure antiviral in New Zealand White rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans","volume":"3","author":"Rice","year":"2011","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.antiviral.2015.02.007_b0065","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/v3020063","article-title":"Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand White rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans","volume":"3","author":"Rice","year":"2011","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2015.02.007_b0070","unstructured":"Tran, P.T., Cargill, V., 2011. Food and Drug Administration Center for Drug Evaluation and Research (pdf document) Summary Minutes of the Antiviral Drugs Advisory Committee December 14\u201315, 2011. Retrieved from <http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AntiviralDrugsAdvisoryCommittee\/UCM294882.pdf>."},{"key":"10.1016\/j.antiviral.2015.02.007_b0075","unstructured":"U. S. Food and Drug Administration\/Center for Drug Evaluation and Research. 2014. Guidance for Industry: Product Development Under the Animal Rule, Washington, DC."},{"key":"10.1016\/j.antiviral.2015.02.007_b0080","doi-asserted-by":"crossref","unstructured":"Zaitseva, M., McCullough, K., Cruz, S., Thomas, A., Diaz, C., Keilholz, L., Grossi, I., Trost, L. and Golding, H. 2015 (expected). Post-challenge administration of brincidofovir protects normal and immune-deficient mice reconstituted with limited numbers of T cells from lethal challenge with IHD-J-Luc vaccinia virus. J. Virol. Accepted manuscript posted online 14 January 2015, doi: 10.1128\/JVI.03340-1.","DOI":"10.1128\/JVI.03340-14"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215000467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215000467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:26:25Z","timestamp":1759062385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354215000467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":17,"alternative-id":["S0166354215000467"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.02.007","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy and pharmacokinetics of brincidofovir for the treatment of lethal rabbitpox virus infection: A model of smallpox disease","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}